289 related articles for article (PubMed ID: 30220707)
21. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
22. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
24. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
Corral Sánchez MD; Galán Gómez V; Sastre Urgelles A; Plaza López de Sabando D; Rubio Aparicio P; Martínez Martínez L; Alonso Gamarra E; Pozo Kreilinger JJ; Regojo Zapata RM; López Gutiérrez JC; Antolín Alvarado E; Gómez Martín F; Sánchez Torres AM; Marín Manzano E; González Del Valle L; Pérez-Martínez A
Pediatr Hematol Oncol; 2021 Aug; 38(5):504-509. PubMed ID: 33622165
[TBL] [Abstract][Full Text] [Related]
25. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
27. Larotrectinib: First Global Approval.
Scott LJ
Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
[TBL] [Abstract][Full Text] [Related]
28. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
[TBL] [Abstract][Full Text] [Related]
29. Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.
Hochmair MJ; Setinek U; Krenbek D; Fazekas A; Illini O; Weinlinger C; Draxler H; Marcher M; Valipour A; Müllauer L; Beer L
Clin Lung Cancer; 2020 Mar; 21(2):e49-e53. PubMed ID: 31879191
[No Abstract] [Full Text] [Related]
30. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
[TBL] [Abstract][Full Text] [Related]
31. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
[TBL] [Abstract][Full Text] [Related]
32. A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.
Mançano BM; Dos Reis MB; Moreno DA; de Paula FE; de Almeida Junior CR; Cavalcante CEB; Zanon MF; Santana IVV; Matsushita MM; Reis RM
Pathobiology; 2022; 89(3):178-185. PubMed ID: 35034013
[TBL] [Abstract][Full Text] [Related]
33. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.
Chen Y; Chi P
J Hematol Oncol; 2018 Jun; 11(1):78. PubMed ID: 29880008
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Identification of a novel
Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
[No Abstract] [Full Text] [Related]
35. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
36. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E; Schram AM; Kulick A; Misale S; Won HH; Yaeger R; Razavi P; Ptashkin R; Hechtman JF; Toska E; Cownie J; Somwar R; Shifman S; Mattar M; Selçuklu SD; Samoila A; Guzman S; Tuch BB; Ebata K; de Stanchina E; Nagy RJ; Lanman RB; Houck-Loomis B; Patel JA; Berger MF; Ladanyi M; Hyman DM; Drilon A; Scaltriti M
Nat Med; 2019 Sep; 25(9):1422-1427. PubMed ID: 31406350
[TBL] [Abstract][Full Text] [Related]
37. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
38. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
Hung YP; Fletcher CDM; Hornick JL
Histopathology; 2018 Oct; 73(4):634-644. PubMed ID: 29863809
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
